Sun Pharmaceutical Industries is reportedly evaluating a potential acquisition of Organon & Co, a U.S.-based women's healthcare company, in what could be India's largest cross-border pharma deal. Sun Pharma has submitted a non-binding all-cash bid with $10-14 billion in acquisition financing arranged. The deal, valued at approximately $10 billion including debt, would significantly strengthen Sun Pharma's presence in the U.S. market and women's health sector, though negotiations remain preliminary with no certainty of completion.

The inaugural National Women's Health Summit will take place in Toronto on March 24-25, 2026, bringing together health researchers, clinicians, and advocates to discuss critical women's health issues and potential innovations.

A national women's health summit will be held in Toronto on March 24-25, 2026, bringing together researchers, clinicians, and health advocates to discuss critical women's health issues and drive meaningful change.

The global contraceptive devices market is projected to grow from $20 billion in 2024 to $33 billion by 2032, driven by increased awareness, technological innovations, and changing demographic trends.

A new McKinsey Health Institute report reveals that Canadian women spend 24% more time in poor health than men, potentially costing the economy $37 billion annually by 2040. Women's Health Collective Canada advocates for increased investment in women's health research and care.

A new analysis reveals that investing in women's health could generate $37 billion in annual GDP by 2040, addressing significant health disparities where Canadian women spend 24% more time in poor health compared to men.

MoonLake Immunotherapeutics faced a securities class action lawsuit after reporting disappointing Phase 3 trial results for its sole drug candidate sonelokimab, causing a 90% stock price drop and investor losses.

Women's Health Collective Canada launched Vital Talks, a national online seminar series focusing on women's health, starting with a menopause care event supported by multiple healthcare and research partners.

ACESF launches 'Conversations vitales', a national online seminar series focusing on women's health, starting with a menopause care seminar on October 29, 2025, supported by various healthcare and pharmaceutical partners.

Daré Bioscience reported a Q2 2025 loss with negative revenue, but demonstrated progress in women's health product pipeline, including Sildenafil Cream and Ovaprene, while managing tight liquidity through strategic partnerships and grant funding.

The dysmenorrhea treatment market is experiencing substantial growth driven by increased awareness, advanced diagnostics, and a growing demand for diverse treatment options including painkillers and hormonal therapies.

A class action lawsuit has been filed against Organon & Co. alleging false and misleading statements about business operations and capital allocation, particularly regarding dividend reduction after Dermavant acquisition.